NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Seqirus facility
Seqirus, the world’s second largest influenza vaccine company, has broken ground for a $9 million expansion of its massive manufacturing facility in Holly Springs.

Last week, NCBiotech went live with a new website. As anyone who has launched a website knows, it is a long process capped by a few days of frenzied activity. We’d like to thank our partner Trone Brand Energy for dealing with us through the calm and the frenzy.

A new website really isn’t news in 2017, but our new message is worth talking about: Transformation.

Fortress Biotech logo
The University of North Carolina, a powerhouse in gene therapy research, has signed exclusive licensing agreements with a New York City biotechnology company for three preclinical gene therapies that could treat an eye disease, certain muscular dystrophies and rejection of corneal transplants.

A Research Triangle-based biological data analysis company founded by Duke University researchers expects to launch one spinout in about a month and another in a year to commercialize specific products it is developing.

The Council for Economic Development is teaming up with the 2018 Coulter Investor Forum to bring two premier venture capital investment events to Raleigh.
LaunchBio logo
LaunchBio, a national nonprofit organization that connects entrepreneurs with knowledge, capital and talent in leading life science hubs, will sponsor monthly networking programs in Durham beginning in the new year.
Fervent Pharmaceuticals logo
Fervent Pharmaceuticals of Greenville has successfully submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for FP-101, its proprietary lead drug candidate for treating menopause symptoms.
Mako Medical Laboratories logo
Raleigh-based Mako Medical Laboratories, a fast-growing diagnostic services company, will create 153 jobs over five years in Henderson, where it plans to build a $15.4 million testing facility with warehousing space.
bluebird bio logo
Potential therapies for several rare diseases and cancers will be manufactured in Durham, according to Cambridge-based bluebird bio, which has purchased a 125,000-square foot manufacturing site.
North Carolina is the nation’s best state for business in 2017, according to the business magazine Forbes.
The North Carolina Biotechnology Center has announced the inaugural class of Pfizer-NCBiotech Distinguished Postdoctoral Fellows in Gene Therapy.
Grifols Among Forbes '500 Best Employers Logo'

Two panelists appearing in today’s Jobs Network program at the North Carolina Biotechnology Center will be representing one of the world’s best employers.

Fresenius Kabi building
Fresenius Kabi will expand its drug-manufacturing operations in Wilson, potentially bringing at least 445 new jobs over five years and $100 million in investment.

The U.S. Food and Drug Administration has approved ViiV Healthcare’s two-drug, once-a-day tablet combination to treat infection by a certain type of the human immunodeficiency virus (HIV).

The therapy, Juluca, consists of two previously approved drugs, dolutegravir and rilpivirine. It is the first approved HIV treatment that combines two drugs instead of three or more used in standard HIV treatment. And it's significant that it's a once-daily tablet.